Long-term Anticoagulation in a Patient With Severe Hemophilia A

NCT07314983 · tracked via the Priya Life Science France tracker

Sponsor

University Hospital, Strasbourg, France

Phase

Observational

Started

2025-09-22

Last updated

2026-01-02

Condition(s) studied

Hemophilia A

Study summary

To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII) deficiency of \<1%. Anticoagulation remains a real challenge in these patients, given the precarious hemostatic balance between the bleeding risk associated with anticoagulation and the antithrombotic protection associated with factor VIII deficiency. The advent of new replacement therapies, characterized by FVIII molecules with a prolonged or very prolonged half-life, provides a high level of FVIII coverage (and therefore protection against the risk of bleeding) in patients receiving prophylaxis, thus facilitating the initiation of anticoagulation therapy.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Adult patient (≥ 18 years) with severe hemophilia A * Absence of written objection in the subject's medical record to the reuse of their data for scientific research purposes. Exclusion Criteria: \- Subject having expressed objection to the reuse of their data for scientific research

Primary outcome measure(s)

FVIII Level — Up to 15 months
Factor VIII (FVIII) is a clotting protein: it enables the blood to form a clot to stop bleeding. Its level indicates how well the blood clots, which is useful for diagnosing or monitoring hemophilia A before surgery. General values: * Normal: approximately 50 to 150% * Too low: risk of bleeding * Too high: may increase the risk of clots

Trial sites (1)

Facility	City	Region	Status
Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France	Strasbourg	France	Recruiting

More University Hospital, Strasbourg, France trials in France

Cefazolin Antibiotic Prophylaxis in Ventricular Shunt Surgery: Determination of Cerebrospinal Fluid Concentration During Valve Implantation Recruiting

Late-term Abortions Between 14 and 16 Weeks of Gestation: Comparison of Hemorrhagic Risks in Surgical vs. Medical Abortions Recruiting

Single Arm, Monocentric, Pilot Feasibility Study on an Interactive Virtual Reality Program in 20 Complex In-clinic Palliative Care Patients Starting soon

Combined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism Recruiting

Placental Learning Model for Neurovascular Microsurgery for the Management of Intracranial Aneurysms Recruiting

Other trials for the same condition

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery Recruiting

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors Recruiting

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults Active, not recruiting

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A Active, not recruiting

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07314983 on ClinicalTrials.gov ↗ ← All trials in France